Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TWMP3N !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TWMP3N !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TWF1j0 !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TWF1j0 !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TW6F2g !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TW6F2g !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TW6F2g !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TW6F2g !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVznkr !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVznkr !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVsc9b !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVsc9b !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVkgfk !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVkgfk !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVbXz1 !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVbXz1 !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVSKnB !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVSKnB !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVKFR6 !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TVKFR6 !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TV9VQq !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TV9VQq !
#Oncology #SocialListening #LucidQuest
PEM/Q vs PEM/Len.
ORR: 30% vs 40%.
1yPFS: 39% vs 34%.
1yOS 75% vs 82%.
TRAE: 25% vs 49%
irAE: 20% vs 44% (only 5% G3+)
Treatment every 6 weeks.
@rickyfrazer1.bsky.social
PEM/Q vs PEM/Len.
ORR: 30% vs 40%.
1yPFS: 39% vs 34%.
1yOS 75% vs 82%.
TRAE: 25% vs 49%
irAE: 20% vs 44% (only 5% G3+)
Treatment every 6 weeks.
@rickyfrazer1.bsky.social
#Prostate: Combos w/ iPARP- and Lu- , EZH2
#Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC
#Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh
#Testicular: RPLND advanced Seminoma
#Penile: IO-chemo for advanced Ca
@rickyfrazer1.bsky.social @jmcgrane.bsky.social
#Prostate: Combos w/ iPARP- and Lu- , EZH2
#Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC
#Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh
#Testicular: RPLND advanced Seminoma
#Penile: IO-chemo for advanced Ca
@rickyfrazer1.bsky.social @jmcgrane.bsky.social
@axelmerseburger.bsky.social
@axelmerseburger.bsky.social
@suyogcancer.bsky.social
oncodaily.com/blog/amol-ak...
#ASCOGU25 #Cancer #NigeriaTrial #OncoDaily #Oncology #ProstateCancer #TALAPRO2Trial #Medicine #Health
@suyogcancer.bsky.social
oncodaily.com/blog/amol-ak...
#ASCOGU25 #Cancer #NigeriaTrial #OncoDaily #Oncology #ProstateCancer #TALAPRO2Trial #Medicine #Health
@raffcolo.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/raffael...
#ASCOGU25 #Cancer #OncoDaily #Oncology #Medicine #Health
@raffcolo.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/raffael...
#ASCOGU25 #Cancer #OncoDaily #Oncology #Medicine #Health
@crisbergerot.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/cristia...
#ASCOGU25 #Cancer #CETTRO #CancerResearchHospital #GenitourinaryOncology #OncoDaily #Oncology #Medicine #Health
@crisbergerot.bsky.social
@ascocancer.bsky.social
oncodaily.com/blog/cristia...
#ASCOGU25 #Cancer #CETTRO #CancerResearchHospital #GenitourinaryOncology #OncoDaily #Oncology #Medicine #Health
These results from the STOPCAP meta-analysis were presented at #ASCOGU25 by @dfishstats.bsky.social.
These results from the STOPCAP meta-analysis were presented at #ASCOGU25 by @dfishstats.bsky.social.
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo
#ASCOGU25 #KidneyCancer #OncoGeriatrics
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo
#ASCOGU25 #KidneyCancer #OncoGeriatrics